Miller‐Horn 2008.
Methods | A retrospective cohort study of patients with ADHD attending a clinic over a 2‐year period taking methylphenidate | |
Participants | Number of participants screened: 516 Number of participants included: 150 Number of participants followed up: 137 Number of withdrawals:13 63 took MPH, of which 40 (29.2% of whole sample) took extended release methylphenidate and 23 (16.8%) took immediate release methylphenidate. Diagnosis of ADHD: DSM‐IV (subtype: combined 121 (88.3%), hyperactive‐impulsive 4 (2.9%), inattentive 12 (8.8%)) Age: males: mean 9.9 (SD 3), range 4‐19 years old; females: 10.9 (SD 3.4), range 4‐17 years old IQ: not stated Sex: 109 males, 28 females Methylphenidate‐naïve: 65% Ethnicity: not stated Country: USA Comorbidity: 87 (64%) (type: oppositional defiant disorder/conduct disorder (16%), seizures (15%), learning disabilities (14%), PDD 13%, sleep disturbances (9%), mental retardation/cerebral palsy (7%), chronic headaches (6%), Tourette's (6%), obsessive compulsive disorder/depression (6%)) Comedication: all patients were on monotherapy for medications used in the treatment of ADHD; however, some of the patients were currently being treated for comorbid conditions Sociodemographics: not stated Inclusion criteria
Exclusion criteria
|
|
Interventions | Methylphenidate type: osmotic release oral system (OROS) and immediate release OROS‐methylphenidate dosage: mean 34.2 (SD 13.6) mg/day (range 18‐54) IR‐methylphenidate dosage: mean 23.3 (SD 14.8) mg/day (range 5‐60) Administration schedule: not stated Duration of intervention: not stated Treatment compliance: not stated |
|
Outcomes | Retrospective database analysis. The database contained information on side effects. No other information regarding measurement available | |
Notes | Sample calculation: not stated Ethics approval: approved by the Institutional Review Board at St. Christopher's Hospital for Children in Philadelphia Funding/vested interests/authors' affiliations: not stated Key conclusions of the study authors: atomoxetine showed a significantly lower incidence of headaches than amphetamine/dextroamphetamine XR, amphetamine/dextroamphetamine or OROS‐methylphenidate Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: not stated Supplemental information requested twice in June 2014 with no reply |